APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Cancer Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Therapeutic Cancer Vaccines Market Analysis and Forecast 2026-2032

31 December 2025190 pages

Choose your research edition.

Industry ResearchTherapeutic Cancer Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Cancer Vaccines Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Therapeutic Cancer Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Cancer Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Cancer Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Therapeutic Cancer Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Therapeutic Cancer Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Therapeutic Cancer Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Therapeutic Cancer Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Therapeutic Cancer Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Therapeutic Cancer Vaccines include Merck, GlaxoSmithKline, Bayer, VAXIMM, Northwest Biotherapeutics, Moderna, Mayo Clinic, Avax Technologies and Asterias Biotherapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Therapeutic Cancer Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Therapeutic Cancer Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for Therapeutic Cancer Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Cancer Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Therapeutic Cancer Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Therapeutic Cancer Vaccines revenue, projected growth trends, production technology, application and end-user industry.

Therapeutic Cancer Vaccines Segment by Company

Merck

GlaxoSmithKline

Bayer

VAXIMM

Northwest Biotherapeutics

Moderna

Mayo Clinic

Avax Technologies

Asterias Biotherapeutics

Antigenics

Therapeutic Cancer Vaccines Segment by Type

Non-specific and Cytokine Strategies

Antigen Vaccine

Whole Cell Vaccine

Others

Therapeutic Cancer Vaccines Segment by Application

Breast Cancer

Prostate Cancer

Brain Tumors

Cervical Cancer

Lung Cancer

Bladder Cancer

Others

Therapeutic Cancer Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Cancer Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Therapeutic Cancer Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Therapeutic Cancer Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Cancer Vaccines revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Therapeutic Cancer Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Non-specific and Cytokine Strategies Major Player Table 3. Antigen Vaccine Major Player Table 4. Whole Cell Vaccine Major Player Table 5. Others Major Player Table 6. Global Therapeutic Cancer Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Breast Cancer Major Player Table 8. Prostate Cancer Major Player Table 9. Brain Tumors Major Player Table 10. Cervical Cancer Major Player Table 11. Lung Cancer Major Player Table 12. Bladder Cancer Major Player Table 13. Others Major Player Table 14. Therapeutic Cancer Vaccines Industry Trends Table 15. Therapeutic Cancer Vaccines Industry Drivers Table 16. Therapeutic Cancer Vaccines Industry Opportunities and Challenges Table 17. Therapeutic Cancer Vaccines Industry Restraints Table 18. Global Therapeutic Cancer Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Therapeutic Cancer Vaccines Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Therapeutic Cancer Vaccines Market Share by Region (2021-2026) Table 21. Global Therapeutic Cancer Vaccines Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Therapeutic Cancer Vaccines Market Share by Region (2027-2032) Table 23. Global Therapeutic Cancer Vaccines Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Therapeutic Cancer Vaccines Revenue Market Share by Players (2021-2026) Table 25. Global Therapeutic Cancer Vaccines Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Therapeutic Cancer Vaccines Key Players Headquarters & Area Served Table 27. Global Therapeutic Cancer Vaccines Players, Product Type & Application Table 28. Global Therapeutic Cancer Vaccines Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Therapeutic Cancer Vaccines by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Therapeutic Cancer Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Therapeutic Cancer Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Therapeutic Cancer Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Therapeutic Cancer Vaccines Revenue Market Share by Type (2021-2026) Table 35. Global Therapeutic Cancer Vaccines Revenue Market Share by Type (2027-2032) Table 36. Global Therapeutic Cancer Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Therapeutic Cancer Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Therapeutic Cancer Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Therapeutic Cancer Vaccines Revenue Market Share by Application (2021-2026) Table 40. Global Therapeutic Cancer Vaccines Revenue Market Share by Application (2027-2032) Table 41. Merck Company Information Table 42. Merck Business Overview Table 43. Merck Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Merck Therapeutic Cancer Vaccines Product Portfolio Table 45. Merck Recent Development Table 46. GlaxoSmithKline Company Information Table 47. GlaxoSmithKline Business Overview Table 48. GlaxoSmithKline Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. GlaxoSmithKline Therapeutic Cancer Vaccines Product Portfolio Table 50. GlaxoSmithKline Recent Development Table 51. Bayer Company Information Table 52. Bayer Business Overview Table 53. Bayer Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bayer Therapeutic Cancer Vaccines Product Portfolio Table 55. Bayer Recent Development Table 56. VAXIMM Company Information Table 57. VAXIMM Business Overview Table 58. VAXIMM Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. VAXIMM Therapeutic Cancer Vaccines Product Portfolio Table 60. VAXIMM Recent Development Table 61. Northwest Biotherapeutics Company Information Table 62. Northwest Biotherapeutics Business Overview Table 63. Northwest Biotherapeutics Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Northwest Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio Table 65. Northwest Biotherapeutics Recent Development Table 66. Moderna Company Information Table 67. Moderna Business Overview Table 68. Moderna Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Moderna Therapeutic Cancer Vaccines Product Portfolio Table 70. Moderna Recent Development Table 71. Mayo Clinic Company Information Table 72. Mayo Clinic Business Overview Table 73. Mayo Clinic Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Mayo Clinic Therapeutic Cancer Vaccines Product Portfolio Table 75. Mayo Clinic Recent Development Table 76. Avax Technologies Company Information Table 77. Avax Technologies Business Overview Table 78. Avax Technologies Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Avax Technologies Therapeutic Cancer Vaccines Product Portfolio Table 80. Avax Technologies Recent Development Table 81. Asterias Biotherapeutics Company Information Table 82. Asterias Biotherapeutics Business Overview Table 83. Asterias Biotherapeutics Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Asterias Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio Table 85. Asterias Biotherapeutics Recent Development Table 86. Antigenics Company Information Table 87. Antigenics Business Overview Table 88. Antigenics Therapeutic Cancer Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Antigenics Therapeutic Cancer Vaccines Product Portfolio Table 90. Antigenics Recent Development Table 91. North America Therapeutic Cancer Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 92. North America Therapeutic Cancer Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 93. North America Therapeutic Cancer Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 94. North America Therapeutic Cancer Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 95. North America Therapeutic Cancer Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. North America Therapeutic Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 97. North America Therapeutic Cancer Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 98. Europe Therapeutic Cancer Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 99. Europe Therapeutic Cancer Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 100. Europe Therapeutic Cancer Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 101. Europe Therapeutic Cancer Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 102. Europe Therapeutic Cancer Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe Therapeutic Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 104. Europe Therapeutic Cancer Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 105. China Therapeutic Cancer Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 106. China Therapeutic Cancer Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 107. China Therapeutic Cancer Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 108. China Therapeutic Cancer Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Therapeutic Cancer Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 110. Asia Therapeutic Cancer Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 111. Asia Therapeutic Cancer Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 112. Asia Therapeutic Cancer Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Therapeutic Cancer Vaccines Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Asia Therapeutic Cancer Vaccines Revenue by Region (US$ Million) & (2021-2026) Table 115. Asia Therapeutic Cancer Vaccines Revenue by Region (US$ Million) & (2027-2032) Table 116. SAMEA Therapeutic Cancer Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 117. SAMEA Therapeutic Cancer Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 118. SAMEA Therapeutic Cancer Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 119. SAMEA Therapeutic Cancer Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 120. SAMEA Therapeutic Cancer Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. SAMEA Therapeutic Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 122. SAMEA Therapeutic Cancer Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Therapeutic Cancer Vaccines Image Figure 2. Global Therapeutic Cancer Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Cancer Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Non-specific and Cytokine Strategies Image Figure 5. Antigen Vaccine Image Figure 6. Whole Cell Vaccine Image Figure 7. Others Image Figure 8. Global Therapeutic Cancer Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Therapeutic Cancer Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 10. Breast Cancer Image Figure 11. Prostate Cancer Image Figure 12. Brain Tumors Image Figure 13. Cervical Cancer Image Figure 14. Lung Cancer Image Figure 15. Bladder Cancer Image Figure 16. Others Image Figure 17. Global Therapeutic Cancer Vaccines Market Size (US$ Million) & (2021-2032) Figure 18. Global Therapeutic Cancer Vaccines Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Therapeutic Cancer Vaccines Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Therapeutic Cancer Vaccines Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Therapeutic Cancer Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Therapeutic Cancer Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Therapeutic Cancer Vaccines Revenue Market Share by Type (2021-2032) Figure 25. Global Therapeutic Cancer Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Therapeutic Cancer Vaccines Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Therapeutic Cancer Vaccines Revenue Market Share by Application (2021-2032) Figure 28. North America Therapeutic Cancer Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032) Figure 30. North America Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032) Figure 31. North America Therapeutic Cancer Vaccines Revenue Share by Country (2021-2032) Figure 32. United States Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Therapeutic Cancer Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032) Figure 37. Europe Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032) Figure 38. Europe Therapeutic Cancer Vaccines Revenue Share by Country (2021-2032) Figure 39. Germany Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Therapeutic Cancer Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032) Figure 49. China Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032) Figure 50. Asia Therapeutic Cancer Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032) Figure 52. Asia Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032) Figure 53. Asia Therapeutic Cancer Vaccines Revenue Share by Region (2021-2032) Figure 54. Japan Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Therapeutic Cancer Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032) Figure 62. SAMEA Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032) Figure 63. SAMEA Therapeutic Cancer Vaccines Revenue Share by Country (2021-2032) Figure 64. Brazil Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Therapeutic Cancer Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Non-specific and Cytokine Strategies
  • Antigen Vaccine
  • Whole Cell Vaccine
  • Others
Applications
  • Breast Cancer
  • Prostate Cancer
  • Brain Tumors
  • Cervical Cancer
  • Lung Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Merck
  • GlaxoSmithKline
  • Bayer
  • VAXIMM
  • Northwest Biotherapeutics
  • Moderna
  • Mayo Clinic
  • Avax Technologies
  • Asterias Biotherapeutics
  • Antigenics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Therapeutic Cancer Vaccines Market by Type
  3. 1.2.1 Global Therapeutic Cancer Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Non-specific and Cytokine Strategies
  5. 1.2.3 Antigen Vaccine
  6. 1.2.4 Whole Cell Vaccine
  7. 1.2.5 Others
  8. 1.3 Therapeutic Cancer Vaccines Market by Application
  9. 1.3.1 Global Therapeutic Cancer Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Breast Cancer
  11. 1.3.3 Prostate Cancer
  12. 1.3.4 Brain Tumors
  13. 1.3.5 Cervical Cancer
  14. 1.3.6 Lung Cancer
  15. 1.3.7 Bladder Cancer
  16. 1.3.8 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Therapeutic Cancer Vaccines Market Dynamics
  1. 2.1 Therapeutic Cancer Vaccines Industry Trends
  2. 2.2 Therapeutic Cancer Vaccines Industry Drivers
  3. 2.3 Therapeutic Cancer Vaccines Industry Opportunities and Challenges
  4. 2.4 Therapeutic Cancer Vaccines Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Therapeutic Cancer Vaccines Market Perspective (2021-2032)
  2. 3.2 Global Therapeutic Cancer Vaccines Growth Trends by Region
  3. 3.2.1 Global Therapeutic Cancer Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Therapeutic Cancer Vaccines Market Size by Region (2021-2026)
  5. 3.2.3 Global Therapeutic Cancer Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Therapeutic Cancer Vaccines Revenue by Players
  2. 4.1.1 Global Therapeutic Cancer Vaccines Revenue by Players (2021-2026)
  3. 4.1.2 Global Therapeutic Cancer Vaccines Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Therapeutic Cancer Vaccines Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Therapeutic Cancer Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Therapeutic Cancer Vaccines Key Players Headquarters & Area Served
  7. 4.4 Global Therapeutic Cancer Vaccines Players, Product Type & Application
  8. 4.5 Global Therapeutic Cancer Vaccines Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Therapeutic Cancer Vaccines Market CR5 and HHI
  11. 4.6.3 2025 Therapeutic Cancer Vaccines Tier 1, Tier 2, and Tier 3
5 Therapeutic Cancer Vaccines Market Size by Type
  1. 5.1 Global Therapeutic Cancer Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Therapeutic Cancer Vaccines Revenue by Type (2021-2032)
  3. 5.3 Global Therapeutic Cancer Vaccines Revenue Market Share by Type (2021-2032)
6 Therapeutic Cancer Vaccines Market Size by Application
  1. 6.1 Global Therapeutic Cancer Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Therapeutic Cancer Vaccines Revenue by Application (2021-2032)
  3. 6.3 Global Therapeutic Cancer Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck Therapeutic Cancer Vaccines Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 GlaxoSmithKline
  8. 7.2.1 GlaxoSmithKline Company Information
  9. 7.2.2 GlaxoSmithKline Business Overview
  10. 7.2.3 GlaxoSmithKline Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Therapeutic Cancer Vaccines Product Portfolio
  12. 7.2.5 GlaxoSmithKline Recent Developments
  13. 7.3 Bayer
  14. 7.3.1 Bayer Company Information
  15. 7.3.2 Bayer Business Overview
  16. 7.3.3 Bayer Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bayer Therapeutic Cancer Vaccines Product Portfolio
  18. 7.3.5 Bayer Recent Developments
  19. 7.4 VAXIMM
  20. 7.4.1 VAXIMM Company Information
  21. 7.4.2 VAXIMM Business Overview
  22. 7.4.3 VAXIMM Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  23. 7.4.4 VAXIMM Therapeutic Cancer Vaccines Product Portfolio
  24. 7.4.5 VAXIMM Recent Developments
  25. 7.5 Northwest Biotherapeutics
  26. 7.5.1 Northwest Biotherapeutics Company Information
  27. 7.5.2 Northwest Biotherapeutics Business Overview
  28. 7.5.3 Northwest Biotherapeutics Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Northwest Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
  30. 7.5.5 Northwest Biotherapeutics Recent Developments
  31. 7.6 Moderna
  32. 7.6.1 Moderna Company Information
  33. 7.6.2 Moderna Business Overview
  34. 7.6.3 Moderna Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Moderna Therapeutic Cancer Vaccines Product Portfolio
  36. 7.6.5 Moderna Recent Developments
  37. 7.7 Mayo Clinic
  38. 7.7.1 Mayo Clinic Company Information
  39. 7.7.2 Mayo Clinic Business Overview
  40. 7.7.3 Mayo Clinic Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Mayo Clinic Therapeutic Cancer Vaccines Product Portfolio
  42. 7.7.5 Mayo Clinic Recent Developments
  43. 7.8 Avax Technologies
  44. 7.8.1 Avax Technologies Company Information
  45. 7.8.2 Avax Technologies Business Overview
  46. 7.8.3 Avax Technologies Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Avax Technologies Therapeutic Cancer Vaccines Product Portfolio
  48. 7.8.5 Avax Technologies Recent Developments
  49. 7.9 Asterias Biotherapeutics
  50. 7.9.1 Asterias Biotherapeutics Company Information
  51. 7.9.2 Asterias Biotherapeutics Business Overview
  52. 7.9.3 Asterias Biotherapeutics Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Asterias Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
  54. 7.9.5 Asterias Biotherapeutics Recent Developments
  55. 7.10 Antigenics
  56. 7.10.1 Antigenics Company Information
  57. 7.10.2 Antigenics Business Overview
  58. 7.10.3 Antigenics Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Antigenics Therapeutic Cancer Vaccines Product Portfolio
  60. 7.10.5 Antigenics Recent Developments
8 North America
  1. 8.1 North America Therapeutic Cancer Vaccines Revenue (2021-2032)
  2. 8.2 North America Therapeutic Cancer Vaccines Revenue by Type (2021-2032)
  3. 8.2.1 North America Therapeutic Cancer Vaccines Revenue by Type (2021-2026)
  4. 8.2.2 North America Therapeutic Cancer Vaccines Revenue by Type (2027-2032)
  5. 8.3 North America Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032)
  6. 8.4 North America Therapeutic Cancer Vaccines Revenue by Application (2021-2032)
  7. 8.4.1 North America Therapeutic Cancer Vaccines Revenue by Application (2021-2026)
  8. 8.4.2 North America Therapeutic Cancer Vaccines Revenue by Application (2027-2032)
  9. 8.5 North America Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032)
  10. 8.6 North America Therapeutic Cancer Vaccines Revenue by Country
  11. 8.6.1 North America Therapeutic Cancer Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Therapeutic Cancer Vaccines Revenue by Country (2021-2026)
  13. 8.6.3 North America Therapeutic Cancer Vaccines Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Therapeutic Cancer Vaccines Revenue (2021-2032)
  2. 9.2 Europe Therapeutic Cancer Vaccines Revenue by Type (2021-2032)
  3. 9.2.1 Europe Therapeutic Cancer Vaccines Revenue by Type (2021-2026)
  4. 9.2.2 Europe Therapeutic Cancer Vaccines Revenue by Type (2027-2032)
  5. 9.3 Europe Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032)
  6. 9.4 Europe Therapeutic Cancer Vaccines Revenue by Application (2021-2032)
  7. 9.4.1 Europe Therapeutic Cancer Vaccines Revenue by Application (2021-2026)
  8. 9.4.2 Europe Therapeutic Cancer Vaccines Revenue by Application (2027-2032)
  9. 9.5 Europe Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032)
  10. 9.6 Europe Therapeutic Cancer Vaccines Revenue by Country
  11. 9.6.1 Europe Therapeutic Cancer Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Therapeutic Cancer Vaccines Revenue by Country (2021-2026)
  13. 9.6.3 Europe Therapeutic Cancer Vaccines Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Therapeutic Cancer Vaccines Revenue (2021-2032)
  2. 10.2 China Therapeutic Cancer Vaccines Revenue by Type (2021-2032)
  3. 10.2.1 China Therapeutic Cancer Vaccines Revenue by Type (2021-2026)
  4. 10.2.2 China Therapeutic Cancer Vaccines Revenue by Type (2027-2032)
  5. 10.3 China Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032)
  6. 10.4 China Therapeutic Cancer Vaccines Revenue by Application (2021-2032)
  7. 10.4.1 China Therapeutic Cancer Vaccines Revenue by Application (2021-2026)
  8. 10.4.2 China Therapeutic Cancer Vaccines Revenue by Application (2027-2032)
  9. 10.5 China Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Therapeutic Cancer Vaccines Revenue (2021-2032)
  2. 11.2 Asia Therapeutic Cancer Vaccines Revenue by Type (2021-2032)
  3. 11.2.1 Asia Therapeutic Cancer Vaccines Revenue by Type (2021-2026)
  4. 11.2.2 Asia Therapeutic Cancer Vaccines Revenue by Type (2027-2032)
  5. 11.3 Asia Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032)
  6. 11.4 Asia Therapeutic Cancer Vaccines Revenue by Application (2021-2032)
  7. 11.4.1 Asia Therapeutic Cancer Vaccines Revenue by Application (2021-2026)
  8. 11.4.2 Asia Therapeutic Cancer Vaccines Revenue by Application (2027-2032)
  9. 11.5 Asia Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032)
  10. 11.6 Asia Therapeutic Cancer Vaccines Revenue by Country
  11. 11.6.1 Asia Therapeutic Cancer Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Therapeutic Cancer Vaccines Revenue by Country (2021-2026)
  13. 11.6.3 Asia Therapeutic Cancer Vaccines Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Therapeutic Cancer Vaccines Revenue (2021-2032)
  2. 12.2 SAMEA Therapeutic Cancer Vaccines Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Therapeutic Cancer Vaccines Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Therapeutic Cancer Vaccines Revenue by Type (2027-2032)
  5. 12.3 SAMEA Therapeutic Cancer Vaccines Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Therapeutic Cancer Vaccines Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Therapeutic Cancer Vaccines Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Therapeutic Cancer Vaccines Revenue by Application (2027-2032)
  9. 12.5 SAMEA Therapeutic Cancer Vaccines Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Therapeutic Cancer Vaccines Revenue by Country
  11. 12.6.1 SAMEA Therapeutic Cancer Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Therapeutic Cancer Vaccines Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Therapeutic Cancer Vaccines Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst